Jefferies analyst Akash Tewari maintains $argenx SE (ARGX.US)$ with a buy rating, and maintains the target price at $689.
According to TipRanks data, the analyst has a success rate of 44.3% and a total average return of 10.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $argenx SE (ARGX.US)$'s main analysts recently are as follows:
The decision to proceed to Phase 3 across all three myositis subtypes is viewed favorably and is seen as bolstering the future value of the pipeline, although it may not significantly impact stock movement. Currently, the model has been updated to incorporate a 70% probability of success for myositis, with adjustments anticipated following the full data reveal at an upcoming medical conference.
After Argenx announced clinical proof-of-concept in myositis, with subQ efgart demonstrating statistically significant improvements across all three myositis subtypes in Phase 2, it is anticipated that broader leadership in the autoimmune category could be solidified. Detailed results are expected to be shared at a future medical meeting.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
富瑞集团分析师Akash Tewari维持$argenx SE (ARGX.US)$买入评级，维持目标价689美元。
根据TipRanks数据显示，该分析师近一年总胜率为44.3%，总平均回报率为10.3%。
此外，综合报道，$argenx SE (ARGX.US)$近期主要分析师观点如下：
决定在所有三种肌炎亚型中继续进行第三阶段被认为是有利的，并被视为增强了管线的未来价值，尽管可能不会显著影响股票走势。目前，模型已经更新，将肌炎的成功概率调整为70％，预计在即将举行的医学会议上完整披露数据后将进行调整。
在Argenx宣布在肌炎中实现临床概念证明后，经皮注射efgart在第2阶段显示出在所有三种肌炎亚型中取得了统计学上显著的改善，预计在自身免疫类别中拓展更广泛的领导地位将得以巩固。详细结果预计将在未来的医学会议上分享。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
